Zanubrutinib (Brukinsa®) – Waldenström's disease, first-line (chemo-immunotherapy unsuitable) or after at least 1 previous therapy
Dossier: BeiGene Germany GmbH
New distributor: BeiGene Netherlands B.V.
|G-BA procedure ID||2021-12-15-D-761|
|Therapeutic area||Oncological diseases|
|Reason for procedure||Initial assessment|
BRUKINSA monotherapy is used to treat adult patients with Morbus Waldenström (MW) who have received at least one prior therapy, or for first-line therapy in patients who are not suitable for chemo-immunotherapy.
|Adults with Morbus Waldenström (MW) who have received at least one prior therapy or adults without prior therapy who are not suitable for chemoimmunotherapy||A patient-specific therapy taking into account the general condition and, if applicable, previous therapies and the duration of remission after initial therapy.|
9. Associated procedures
|Resolution||INN||Brand name||Indication||Patients||Additional benefit|
|15.12.2021 – 16.06.2022||Zanubrutinib||Brukinsa®||Waldenström's disease, first-line (chemo-immunotherapy unsuitable) or after at least 1 previous therapy||450 – 1,050|
<< List of all resolutions